Thoma Bravo values Greenphire at ~$1.1bn as tech transforms clinical research

Already proving a home run investment for Riverside, Greenphire remains on a fast growth track as the clinical research market remains largely dominated by manual, paper-based workflows.

DealsHealthcareFeaturedTop Stories